Tenofovir exalidex

Drug Profile

Tenofovir exalidex

Alternative Names: CMX 157; HDP-Tenofovir; Hexadecyloxypropyl-tenofovir; TXL™

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chimerix
  • Developer Chimerix; ContraVir Pharmaceuticals
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B
  • Suspended HIV infections

Most Recent Events

  • 08 Aug 2017 ContraVir completes the phase IIa portion of a phase Ib/IIa trial in Hepatitis B treatment in Thailand
  • 20 Apr 2017 Additional interim efficacy, adverse events and pharmacokinetics data from a phase Ib/IIa trial in Hepatitis B released by ContraVir Pharmaceuticals
  • 11 Nov 2016 Updated safety and pharmacokinetics data from a phase I trial (Healthy volunteers) and phase Ib/IIa trial in Hepatitis B presented at The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top